REVERSIN 121
REVERSIN 121 Basic information
- Product Name:
- REVERSIN 121
- Synonyms:
-
- REVERSIN 121
- BOC-ASP(OBZL)-LYS(Z)-OTBU
- L-Lysine, N-[(1,1-dimethylethoxy)carbonyl]-L-α-aspartyl-N6-[(phenylmethoxy)carbonyl]-, 2-(1,1-dimethylethyl) 1-(phenylmethyl) ester
- CAS:
- 174630-04-7
- MF:
- C34H47N3O9
- MW:
- 641.75
- Mol File:
- Mol File
REVERSIN 121 Chemical Properties
- Melting point:
- 200°C
- Boiling point:
- 786.8±60.0 °C(Predicted)
- Density
- 1.163±0.06 g/cm3(Predicted)
- storage temp.
- −20°C
- solubility
- DMSO or ethanol: soluble
- form
- powder
- pka
- 10.75±0.46(Predicted)
- color
- white
MSDS
- Language:English Provider:SigmaAldrich
REVERSIN 121 Usage And Synthesis
Description
Reversin 121 is a hydrophobic peptide chemosensitizer that can reverse P-glycoprotein-mediated multidrug resistance. It binds to the P-glycoprotein multidrug transporter (MDR1) with a Kd value of 77 nM. Reversin 121 modulates P-glycoprotein ATPase activity in Sf9 insect cell membranes expressing human MDR1, plasma membrane vesicles from multidrug-resistant cells, and reconstituted proteoliposomes as well as in a variety of MDR1-expressing intact tumor cells.
Uses
Reversin 121 has been used to determine the activity of P-glycoprotein in human retinal pigment epithelium.
General Description
Reversin 121 is an analog of reversin and a dipeptide derivative.
Biochem/physiol Actions
Peptide chemosensitizer, inhibitor of P-glycoprotein.
in vivo
Reversin 121 (2.5 mg/kg, plus 5-fluorouracil, 35 mg/kg/day, i.p.) decreases tumor size and prevalence of metastases[1].
| Animal Model: | Orthotopic pancreatic carcinoma mouse model[1]. |
| Dosage: | 2.5 mg/kg, plus 5-fluorouracil, 35 mg/kg/day |
| Administration: | Intraperitoneal injection (i.p.), 5 days a week |
| Result: | Decreased in MRP3-positive cells. |
References
[1] FRANCES J SHAROM . Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells[J]. Biochemical pharmacology, 1999, 58 4: Pages 571-586. DOI: 10.1016/s0006-2952(99)00139-2
[2] EUNICE L KWAK. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102 21: 7665-7670. DOI: 10.1073/pnas.0502860102
[3] PRIYANKA S. RANA . Calibration and characterization of intracellular Asante Potassium Green probes, APG-2 and APG-4[J]. Analytical biochemistry, 2019, 567: Pages 8-13. DOI: 10.1016/j.ab.2018.11.024
REVERSIN 121Supplier
- Tel
- 021-61415566 800-8193336
- orderCN@merckgroup.com
- Tel
- 021-65675885 18964387627
- info@efebio.com
- Tel
- 0571-87213919
- Eric@peptidego.com
- Tel
- 400-9205774
- sales@glpbio.cn
- Tel
- 18818260767
- sales@chemegen.com